Per Magnusson

Prof. Per Magnusson

orcid

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2017 in Nature Reviews Nephrology
Verified
Journal Article
Open access
PDF file
MHMathias Haarhaus
Mathias Haarhaus
VBVincent Brandenburg
Vincent Brandenburg
Kamyar Kalantar-ZadehKamyar Kalantar-Zadeh
Kamyar Kalantar-Zadeh
PSPeter Stenvinkel
Peter Stenvinkel
PMPer Magnusson
Per Magnusson
Cardiovascular disease is the main cause of early death in the settings of chronic kidney disease (CKD), type 2 diabetes mellitus (T2DM), and ageing. Cardiovascular events can be caused by an imbalance between promoters and inhibitors of mineralization, which leads to vascular calcification. This process is akin to skeletal mineralization, which is carefully regulated and in which isozymes of alkaline phosphatase (ALP) have a crucial role. Four genes encode ALP isozymes in humans. Intestinal, placental and germ cell ALPs are tissue-specific, whereas the tissue-nonspecific isozyme of ALP (TNALP) is present in several tissues, including bone, liver and kidney. TNALP has a pivotal role in bone calcification. Experimental overexpression of TNALP in the vasculature is sufficient to induce vascular calcification, cardiac hypertrophy and premature death, mimicking the cardiovascular phenotype often found in CKD and T2DM. Intestinal ALP contributes to the gut mucosal defence and intestinal and liver ALPs might contribute to the acute inflammatory response to endogenous or pathogenic stimuli. Here we review novel mechanisms that link ALP to vascular calcification, inflammation, and endothelial dysfunction in kidney and cardiovascular diseases. We also discuss new drugs that target ALP, which have the potential to improve cardiovascular outcomes without inhibiting skeletal mineralization.

16 March 2017 in Calcified Tissue International
Verified
Journal Article
Open access
PDF file
CLCecilia Halling Linder
Cecilia Halling Linder
BEBarbro Ek-Rylander
Barbro Ek-Rylander
MKMichael Krumpel
Michael Krumpel
MNMaria Norgård
Maria Norgård
SNSonoko Narisawa
Sonoko Narisawa
PMPer Magnusson
Per Magnusson
Phosphorylated osteopontin (OPN) inhibits hydroxyapatite crystal formation and growth, and bone alkaline phosphatase (BALP) promotes extracellular mineralization via the release of inorganic phosphate from the mineralization inhibitor inorganic pyrophosphate (PPi). Tartrate-resistant acid phosphatase (TRAP), produced by osteoclasts, osteoblasts, and osteocytes, exhibits potent phosphatase activity towards OPN; however, its potential capacity as a regulator of mineralization has not previously been addressed. We compared the efficiency of BALP and TRAP towards the endogenous substrates for BALP, i.e., PPi and pyridoxal 5′-phosphate (PLP), and their impact on mineralization in vitro via dephosphorylation of bovine milk OPN. TRAP showed higher phosphatase activity towards phosphorylated OPN and PPi compared to BALP, whereas the activity of TRAP and BALP towards PLP was comparable. Bovine milk OPN could be completely dephosphorylated by TRAP, liberating all its 28 phosphates, whereas BALP dephosphorylated at most 10 phosphates. OPN, dephosphorylated by either BALP or TRAP, showed a partially or completely attenuated phosphorylation-dependent inhibitory capacity, respectively, compared to native OPN on the formation of mineralized nodules. Thus, there are phosphorylations in OPN important for inhibition of mineralization that are removed by TRAP but not by BALP. In conclusion, our data indicate that both BALP and TRAP can alleviate the inhibitory effect of OPN on mineralization, suggesting a potential role for TRAP in skeletal mineralization. Further studies are warranted to explore the possible physiological relevance of TRAP in bone mineralization.

19 May 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
MHMathias Haarhaus
Mathias Haarhaus
GCGiuseppe Cianciolo
Giuseppe Cianciolo
SBSimona Barbuto
Simona Barbuto
Gaetano La MannaGaetano La Manna
Gaetano La Manna
LGLorenzo Gasperoni
Lorenzo Gasperoni
PMPer Magnusson
Per Magnusson
Alkaline phosphatase (ALP) is an evolutionary conserved enzyme and widely used biomarker in clinical practice. Tissue-nonspecific alkaline phosphatase (TNALP) is one of four human isozymes that are expressed as distinct TNALP isoforms after posttranslational modifications, mainly in bone, liver, and kidney tissues. Beyond the well-known effects on bone mineralization, the bone ALP (BALP) isoforms (B/I, B1, B1x, and B2) are also involved in the pathogenesis of ectopic calcification. This narrative review summarizes the recent clinical investigations and mechanisms that link ALP and BALP to inflammation, metabolic syndrome, vascular calcification, endothelial dysfunction, fibrosis, cardiovascular disease, and mortality. The association between ALP, vitamin K, bone metabolism, and fracture risk in patients with chronic kidney disease (CKD) is also discussed. Recent advances in different pharmacological strategies are highlighted, with the potential to modulate the expression of ALP directly and indirectly in CKD–mineral and bone disorder (CKD-MBD), e.g., epigenetic modulation, phosphate binders, calcimimetics, vitamin D, and other anti-fracture treatments. We conclude that the significant evidence for ALP as a pathogenic factor and risk marker in CKD-MBD supports the inclusion of concrete treatment targets for ALP in clinical guidelines. While a target value below 120 U/L is associated with improved survival, further experimental and clinical research should explore interventional strategies with optimal risk–benefit profiles. The future holds great promise for novel drug therapies modulating ALP.

1 October 2013 in American Journal of Kidney Diseases
Verified
Journal Article
Closed access
SSSunita Sardiwal
Sunita Sardiwal
PMPer Magnusson
Per Magnusson
DGDavid J.A. Goldsmith
David J.A. Goldsmith
ELEdmund J. Lamb
Edmund J. Lamb

1 February 2020 in Clinica Chimica Acta
Verified
Journal Article
Closed access
ANAdrien Nizet
Adrien Nizet
ECEtienne Cavalier
Etienne Cavalier
PSPeter Stenvinkel
Peter Stenvinkel
MHMathias Haarhaus
Mathias Haarhaus
PMPer Magnusson
Per Magnusson

1 December 2007 in Neuromuscular Disorders
Verified
Journal Article
Closed access
ASAnn-Charlott Söderpalm
Ann-Charlott Söderpalm
PMPer Magnusson
Per Magnusson
AÅAnne-Christine Åhlander
Anne-Christine Åhlander
JKJón Karlsson
Jón Karlsson
AKAnna-Karin Kroksmark
Anna-Karin Kroksmark
DSDiana Swolin-Eide
Diana Swolin-Eide